Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

This is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled. The treatment is Atezolizumab + Paclitaxel + Carboplatin 3 cycles as neoadjuvant/induction treatment. After the induction treatment every patient will be evaluated by a multidisciplinary team in each participant hospital to decide if the patient is candidate for surgery or not. Depending on the decision each patient will be treated in a different way. The primary objective is to evaluate the Progression free survival (PFS). The total trial duration w

Trial Details

NCT ID
NCT07153445
Phase
PHASE2
Sponsor
Fundación GECP
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Atezolizumab
  • Paclitaxel
  • Carboplatin
Locations (sample)
  • Alicante, Alicante, Spain|38.34517,-0.48149
  • Badalona, Barcelona, Spain|41.45004,2.24741
  • Barcelona, Barcelona, Spain|41.38879,2.15899
  • Barcelona, Barcelona, Spain|41.38879,2.15899
  • Barcelona, Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Previously untreated patients with histologically- or cytologically- documented Non Small-Cell Lung Cancer (NSCLC) who present stage IIIA - IIIB di…
  • Confirm the absence of distant disease
  • ECOG (Performance status) 0-1
  • Adequate hematologic and organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →